Study STML-901-0119 is a multi-center, open-label, dose-escalation and regimen-finding study aimed to investigate the safety, PK, and PD of SL-901 in patients with advanced solid tumors.~Part 1a will take place in up to 5 centers in the United Kingdom and follow a 3+3 dose-escalation design to determine the maximum tolerated dose of SL-901 when administered on both a QD and BID schedule. Eligible patients will be enrolled and receive treatment with SL-901 daily on a 28-day cycle. SL-901 will be administered orally and the dose regimen will depend on the cohort and regimen in which the patient is enrolled.~Part 1b will utilize the selected dose from Part 1a, and the clinical activity of SL-901 will be evaluated in patients with advanced solid tumors known to have specific genetic alterations, who may derive benefit from treatment with a phosphoinositide 3-kinase (PI3K) inhibitor.
Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with Advanced Solid Tumors.